Objectives: The aim of this study was to evaluate the efficacy of neoadjuvant gemcitabine and cisplatin (GC) therapy for muscle-invasive bladder cancer (MIBC). Methods: We retrospectively evaluated patients who underwent neoadjuvant GC therapy followed by radical cystectomy from April 2009 through December 2015 in the Sapporo Medical University Urologic Consortium. The efficacy of neoadjuvant chemotherapy (NAC) was assessed based on the pathological T0 (pT0) rate in radical cystectomy specimens, and the recurrence-free survival, cause-specific survival and overall survival (OS) rates. To compare the oncological benefit of NC with GC to that of the methotrexate, vinblastine, adriamycin and cisplatin (MVAC) regimen, we also utilized historical clinical data of patients who were treated with MVAC as NAC followed by radical cystectomy in our institute from 1986 through 2010. Results: Fifty-eight patients receiving neoadjuvant GC therapy and 74 receiving neoadjuvant MVAC were included. The pT0 achieving rates were comparable between the two groups (20.7% vs. 18.9%, P = 0.83). Neoadjuvant GC was associated with a better 2-year OS rate than neoadjuvant MVAC for clinical T2 disease (95.2% vs. 70.8%, P = 0.036). In contrast, in patients with clinical T3 or more advanced disease, neoadjuvant MVAC provided more pT0 (20.0% vs. 5.6%, P = 0.07) and better 2-year OS than neoadjuvant GC (71.1% vs. 55.0%, P = 0.142), although the difference did not reach statistical significance. Conclusions: Neoadjuvant GC had no inferiority in oncological outcomes to MVAC for MIBC.
Introduction
Bladder cancer is one of the most annoying diseases for urologists because of the high recurrence rate and mortality, especially in muscle-invasive bladder cancer (MIBC). Although radical cystectomy (RCx) with urinary diversion is performed in patients with non-metastatic MIBC, around half of them die of disease within 5 years (1) .
Several studies had shown the oncological benefit of neoadjuvant chemotherapy (NAC) followed by RCx compared with RCx alone. For instance, the SWOG8710 Phase 3 randomized trial, which included 317 MIBC patients, demonstrated that three cycles of NAC with methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) provided longer survival and a higher pathologic complete response (pT0) rate than RCx alone (2) . Moreover, in a meta-analysis, cisplatin (CDDP)-based NAC showed a survival benefit in MIBC patients (3) . A randomized Phase 3 trial for Japanese patients also demonstrated that two cycles of NAC-MVAC prolonged survival and increased the rate of pT0 compared with RCx alone (4) . The combination of CDDP, methotrexate and vinblastine (CMV) and following RCx was evaluated in the updated BA06 30 894 trial (5) . The mortality rate decreased significantly by 16% in the arm employing RCx with NAC-CMV therapy. Based on these data, utilizing CDDP-based NAC for MIBC is widespread currently.
For metastatic bladder cancer patients, MVAC was the standard regimen (6) . However, because of its lesser toxicity and non-inferior oncological outcome, gemcitabine plus cisplatin (GC) chemotherapy became the new standard regimen in this setting (7, 8) . Gradually, the indication for GC therapy has expanded to the neoadjuvant setting (9) (10) (11) . Although these previous reports supported GC chemotherapy in the neoadjuvant setting for MIBC, the efficacy was evaluated by achievement of pT0, but not by overall survival (OS) or cause-specific survival (CSS). Moreover, only limited data are available for Japanese patients. Therefore, we investigated the efficacy of NAC-GC therapy followed by RCx, including pathological and survival outcomes in a Japanese multicenter retrospective study.
Methods

Study population
Clinical data of MIBC patients who received NAC-GC therapy followed by RCx between April 2009 and December 2015 were retrospectively obtained from ten hospitals of the Sapporo Medical University Urologic Oncology Consortium. Patients having clinical node-positive status and distant metastasis were excluded. After exclusion of the patients having node-positive disease, 58 patients were included in the cohort for NAC-GC in this study. All patients were evaluated preoperatively by computed tomography (CT) for distant and lymph node metastases.
To compare oncological outcomes with the established regimen, we utilized historical clinical data of patients who underwent NAC-MVAC therapy followed by RCx in our hospital from 1986 through 2010. The treatment was done according to previous reports (4).
Neoadjuvant GC therapy schedule and toxicity evaluation
In the NAC-GC cohort, all patients underwent 21-day or 28-day scheduled NAC-GC for 2-4 cycles. Patients were given 1000 mg/m 2 of GEM on Days 1 and 8 on a 21-day schedule, and Days 1, 8 and 15 on a 28-day schedule. In both schedules, 70 mg/m 2 of CDDP was given on Day 2. All patients underwent periodic physical examinations and blood tests during the chemotherapy. The toxicity and adverse events of chemotherapy were evaluated using the CTCAE v 4.0 classification. Doses of chemotherapeutic agents were adjusted according to the renal function in each cycle.
Surgical technique
All patients underwent open or laparoscopic RCx concomitantly with pelvic lymph node dissection (PLND) and urinary diversion.
The decision for the type of urinary diversion was made based on tumor location, patient preference and renal function. PLND included the removal of all lymphatic and fibroadipose tissues in anatomic Level 1 (lymph nodes of Cloquet, internal iliac, external iliac, obturator), Level 2 (presacral, common iliac, marseilles) or Level 3 (para-aortic, para-caval, aorta-caval).
Endpoints and statistical analyses
The primary endpoint was OS and the secondary endpoints were CSS, recurrence-free survival (RFS) and achievement of pathological T0 (pT0) status at the pathological examination of cystectomy specimens. Statistical differences between groups were assessed using Fisher's exact probability test, the chi-square test for categorical variables and Student's t test for continuous variables. P < 0.05 (two-sided) was considered statistically significant. Survival after RCx was examined by using the Kaplan-Meier method, and survivals in the subgroups were compared using the log-rank test. To determine factors influencing RFS, CSS and OS, Cox proportional hazards analysis was performed. All data were analyzed using EZR ver.1.35 (Saitama Medical Center, Jichi Medical University) (12) . The study was approved by the Ethical Committee of Sapporo Medical University School of Medicine (Institutional review board number 262-94).
Results
Patient characteristics
Fifty-eight patients who received NAC-GC were included in this study. As a historical control, data of 74 patients who received NAC-MVAC in our hospital were collected. Patient characteristics are shown in Table 1 . Since NAC-MVAC was performed between 1986 and 2010, the follow-up period was significantly longer than for NAC-GC patients.
Dose reduction and adverse events with NAC-GC
In the NAC-GC group, 37 patients (64%) underwent a 21-day schedule with GC and 21 patients (36%) a 28-day schedule. Dose reduction of cisplatin was decided for 11 patients (19%) due to impaired renal function or adverse events. Grades 3-5 adverse events were collected from medical records. No Grade 5 adverse event was observed. Among the patients treated with NAC-GC, Grade 3 or 4 leukocytopenia, neutrocytopenia, anemia and febrile neutropenia were observed in 12 (20.7%), 28 (48.3%), 6 (10.3%) and 5 (8.6%), respectively. Eight patients needed blood transfusion preoperatively. Intraoperative findings are listed in Table 2 .
Oncological outcomes
RFS, CSS and OS in patients treated with NAC-GC and NAC-MVAC are shown in Fig. 1 . RFS, CSS and OS were not significantly different among the regimens. Patients who achieved pT0 had better RFS and OS in the NAC-GC group (2-year RFS; 91.7% vs. 60.9%, 2-year OS; 91.7% vs. 64.3%, respectively, Fig. 2A-C) .
We compared the rates of acquired pT0 in the cystectomy specimens from the two regimens according to clinical T stage (Table 3) . There were no significant differences. However, NAC-GC was associated with a higher pT0 rate than NAC-MVAC for cT2 disease, whereas the pT0 rate for cT3 or more advanced disease was lower in the NAC-GC group than in the MVAC-GC group. RFS, CSS and OS according to clinical T stage are shown in Fig. 3 . Consistent with the pT0 achievement rates, cT2 patients treated with NAC-GC had better RFS, CSS and OS than those treated with NAC-MVAC (Fig. 3A-C) . Conversely, NAC-MVAC patients having cT3 or more disease had better RFS, CSS and OS than cT3 NAC-GC patients, although the difference was not statistically significant ( Fig. 3A-C) . To evaluate the impacts of clinical and pathological parameters on OS, univariate and multivariate analyses were performed (Table 4) . Interestingly, in patients treated with NAC-GC, the clinical T stage had an impact on OS. In contrast, in those treated with NAC-MVAC, pT0 status achievement had an impact, whereas the clinical T stage did not affect the OS. Discussion CDDP-based NAC followed by RCx with PLND is a standard strategy for MIBC (13) (14) (15) (16) (17) . Several reports demonstrated the survival benefit of NAC for MIBC compared with RCx alone (2-5). For metastatic bladder cancer patients, because of its lesser toxicity and non-inferiority with regard to the survival benefit, GC therapy has been a standard regimen (7, 8) . Based on these data, clinical utilization of NAC-GC therapy is now widespread in the clinical situation despite the lack of Level 1 evidence. A previous report demonstrated that GC was the most used regimen compared with MVAC and DD-MVAC (18) . Importantly, there are also data indicating that NAC prior to RCx does not increase postoperative complications (19) . However, there has been no prospective randomized trial to resolve the issue of utilizing GC in the NAC setting.
Several retrospective studies and meta-analyses have discussed this issue. Kim et al. reported a network meta-analysis comparing NAC-GC and NAC-MVAC effects, which indicated that both regimens achieved pT0 at similar rates (20) . Zagar et al. reported the results of a retrospective multicenter study comparing the pathologic responses to NAC-GC and NAC-MVAC (21) . Although the study was retrospective and lacked survival outcome analysis, they collected a large number of patients (N = 935) treated by NAC followed by RCx, and pT0 achievement did not differ among NAC-GC and NAC-non-GC regimens. Additionally, Galsky et al. reported the results for 146 patients treated with NAC-GC compared with 66 treated with NAC-MVAC (22) . The NAC regimen was not a predictive factor for OS after propensity score matching between the NAC-GC and NAC-MVAC groups (P = 0.17) and the rate of achieving pT0 did not differ among NAC regimens. To the best of our knowledge, Galsky's report was the first study comparing survival between patients treated with NAC-GC and NAC-MVAC. Conversely, Yin et al. reported a two-step meta-analysis (24) . Thus, the controversial issue of which regimen is better or whether they are the same, remains unresolved.
In the present study, we retrospectively collected 58 patients treated with NAC-GC followed by RCx and PLND. Moreover, we utilized data on 74 patients who received NAC-MVAC and consecutive RCx and PLND to compare both pathological and survival outcomes. Despite the retrospective nature of the study and limited number of patients, this report includes the largest number of patients in our country. In addition, our mean follow-up period for the NAC-GC group was 33.2 months, which is the longest series reporting NAC-GC outcomes. The relatively long follow-up period enabled us to assess the survival benefit of NAC for MIBC patients. Similar to previous studies, patients who achieved pT0 status had a better survival rate in our data and the NAC regimen was not a predictor for survival outcome. Interestingly, the rates of achieving pT0 differed among regimens in different clinical T stages. Among cT2 patients, 10 of 22 (45.5%) patients achieved pT0 status in the NAC-GC group but only 4 of 24 (16.6%) did in the NAC-MVAC group. On the other hand, in cT3 patients, only 2 of 36 (5.6%) patients had pT0 results with NAC-GC but 10 of 50 (20%) did with the NAC-MVAC regimen. Although these differences did not reach statistical significance, NAC-MVAC may be more suitable for cT3 or more advanced bladder cancer.
Consistent with the results, Kaplan-Meier analysis demonstrated better survival with NAC-GC for cT2 cases and with NAC-MVAC for cT3 cases (Fig. 3) .
The possibility of different responses according to the clinical T stage with the NAC regimens is a novel insight of the present study. However, we could verify this possibility in previous reports. Zargar et al. (21) included the largest number of patients treated with NAC in their study. According to their article, 86 patients who underwent NAC-MVAC for cT3 or more advanced disease were included. In addition, 182 patients who received NAC-GC for cT3 or more advanced MIBC were also included. Among the 86 patients treated with NAC-MVAC, 21 (24.4%) achieved pT0 status. On the other hand, only 28 of the 182 patients (15.4%) achieved pT0 in the NAC-GC group (P = 0.09, chi-square test). Our findings are quite in accord with those in their series, although they did not reach statistical significance.
For NAC-MVAC it is reported that the effects do not differ among clinical T stages. In the SWOG8710 prospective study, NAC-MVAC had a survival benefit regardless of the clinical T stage (2) . Similarly, in the JCOG0209 study, two courses of NAC-MVAC were performed for the NAC group (4). Among 64 patients assigned to the NAC group, 29 patients had cT3 or more advanced MIBC and 29.6% of them achieved pT0 status, which was higher than the pT0 rate in our NAC-GC group (5.6%). Furthermore, a survival benefit of NAC-MVAC was observed in JCOG0209 regardless of the clinical T stage. Our multivariate analyses indicated that the OS of patients who received NAC-MVAC was affected by the pathological T stage but not the clinical T stage. On the other hand, in the NAC-GC group, the opposite outcome was observed (Table 4 ). These results may indicate different potential effects for advanced clinical T stage bladder cancers according to the NAC regimen. Therefore, further study to verify the relationship between the regimen and clinical T stage is warranted.
In our retrospective study, the number of NAC cycles was different among NAC regimens. The mean numbers of cycles were 3.0 and 2.1 for patients treated with NAC-GC and NAC-MVAC, respectively. More cycles of NAC-MVAC may potentially improve survival in the case of locally advanced disease. On the other hand, an increased number of cycles may be associated with more toxicity and intolerability. Moreover, prolonged NAC may lead to a delay of cystectomy in nonresponders (4) . Further investigations are needed to determine the (25) . Pathological node-negative status was achieved in 48% of the patients and the number of induction chemotherapy cycles was associated with pathological node-negative status achievement.
In our cohort, all of the patients who received neoadjuvant MVAC underwent open radical cystectomy (ORC). In the GC cohort, 17 patients were treated by laparoscopic radical cystectomy (LRC). Since robotic-assisted radical cystectomy (RARC) was not approved in our country until 2018, none of the patients in this study underwent RARC. Although the surgical techniques, open and laparoscopic, differed between the two groups, this might not have influenced the oncological outcomes. Yong et al. reported similar OS rates for LRC and ORC (26) . Albisinni et al. also reported the long-term outcome of LRC (27) . As a result, the oncological outcomes were comparable with those reported in the ORC series.
There are several limitations in our study. First, this was a retrospective study and the treatment eras were quite different between regimens. Unfortunately, since surgical information such as operation time, bleeding and number of lymph nodes dissected in the MVAC group were lacking, we could not compare the surgical information with that for the GC cohort.
In addition, because of the improvement of CT scanning and MRI in the last decade, clinical staging has improved (28) . Thus, some cT3 disease might have been diagnosed as cT2 in the NAC-MVAC cohort. Moreover, histological variants may have affected the pathological response in our data. However, because we were not able to collect complete detailed information, we could not investigate the correlation of variant histology and pathological response. Pokuri et al. reported that variant histology had an effect on the pathological response to NAC (29) .
Since the treatment eras of the two groups were different, we could not exclude the influence of pharmacological improvements such as the use of granulocyte-colony stimulating factor or antiemetic agents, which might affect the completion rate of chemotherapy. Additionally, we could not compare the dose intensities of CDDP in these two regimens in the present study because of a lack of data. In our study, we included 21-day and 28-day NAC-GC courses, which may be a potential limitation.
In the future, not only determination of an appropriate regimen and suitable clinical character for NAC, but also the development of molecular biomarkers to predict the effect of NAC is greatly needed to optimize the treatment strategy (30) (31) (32) .
Conclusions
NAC-GC had no inferiority in oncological outcomes to NAC-MVAC. Thus, NAC-GC may be beneficial for MIBC patients especially, for those with stage cT2.
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